Recent Material Events

Track the latest material events (8-K filings) with AI-powered analysis. Stay informed about major corporate developments, acquisitions, and changes.

📊 979 Events

🤖 AI Analyzed

Recent

📄 Page 71 of 82

Decoy Therapeutics Inc.

8-K February 25, 2026

Key Highlights

Focuses on developing novel therapies for unmet medical needs, a high-growth sec...
Approved a new Equity Incentive Plan to attract, retain, and motivate key talent...
Implementing a reverse stock split to increase share price and meet Nasdaq's min...

Read Analysis

🤖 AI Generated

Southwest Gas Holdings, Inc.

8-K February 25, 2026

Key Highlights

Justin Lee Brown, with deep operational experience within the company's core uti...
The leadership transition is planned and amicable, with Ms. Haller serving as an...
The Board views this as a strategic move to position Southwest Gas for its next ...

Read Analysis

🤖 AI Generated

Driven Brands Holdings Inc.

8-K February 25, 2026

Key Highlights

Strategic divestiture of Auto Glass Now segment to reduce debt.
Generated $170 million in proceeds for debt reduction.
Expected improvement in overall profit margins post-divestiture.

Read Analysis

🤖 AI Generated

DevvStream Corp.

8-K February 25, 2026

Key Highlights

DevvStream Corp. received a crucial extension from Nasdaq, preventing immediate ...
The company has until May 18, 2026, to regain compliance with Nasdaq's minimum s...
This extension offers a critical window for the company to address its financial...

Read Analysis

🤖 AI Generated

Tevogen Bio Holdings Inc.

8-K February 25, 2026

Key Highlights

Stockholders approved an expanded 2024 Equity Incentive Plan, increasing shares ...
Authorization for a reverse stock split (1:25 to 1:85 ratio) aims to boost the s...
Maintaining the Nasdaq listing is essential for market visibility, access to cap...

Read Analysis

🤖 AI Generated

Incannex Healthcare Inc.

8-K February 25, 2026

Key Highlights

Incannex Healthcare Inc. will implement a 1-for-30 reverse stock split to consol...
The primary goal is to regain and maintain compliance with Nasdaq's minimum bid ...
Fractional shares resulting from the split will be rounded up to the next whole ...

Read Analysis

🤖 AI Generated

Verses AI Inc.

8-K February 25, 2026

Key Highlights

Strategic pivot to core 'Genius' product, now generating revenue with positive p...
Aggressive cost reductions, including a 40% reduction in monthly cash burn and a...
Reaffirmed goal to uplist to Nasdaq, anticipated to improve capital access and s...

Read Analysis

🤖 AI Generated

Starfighters Space, Inc.

8-K February 25, 2026

Key Highlights

Pioneering advanced space technologies, including reusable rocket systems, satel...
Actively engaged in developing next-generation propulsion systems and satellite ...
New CEO, Tim Franta, previously VP of Development, suggests a potential focus on...

Read Analysis

🤖 AI Generated

AmBase Corp

8-K February 25, 2026

Key Highlights

Insider loan provides a critical, short-term cash infusion, averting an immediat...
CEO's personal loan demonstrates strong belief in the company's potential, espec...
The 111 West 57th litigation represents AmBase's core strategy for potential rec...

Read Analysis

🤖 AI Generated

GREIF, INC

8-K February 25, 2026

Key Highlights

Greif divested its entire containerboard business, including CorrChoice, to stre...
The company underwent a significant internal business reorganization, dissolving...
Greif shifted its fiscal year end from October 31st to September 30th, effective...

Read Analysis

🤖 AI Generated

QNB CORP.

8-K February 25, 2026

Key Highlights

All necessary regulatory approvals for the merger have been received from the Bo...
This approval removes a major regulatory hurdle, significantly increasing the li...
The combined entity is projected to command approximately $2.5 billion in total ...

Read Analysis

🤖 AI Generated

Sarepta Therapeutics, Inc.

8-K February 25, 2026

Key Highlights

Elevidys, the first and only FDA-approved gene therapy for DMD, awaits a critica...
Despite missing its primary endpoint in the EMBARK trial, Elevidys has started g...
Sarepta benefits from a strategic partnership with Roche for global commercializ...

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from material event filings with our AI-powered analysis. Track corporate developments, acquisitions, and strategic changes.

Back to Homepage